LEXINGTON, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University of Texas ...
KSQ Therapeutics, Inc. announced today it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279.
然而,破坏PCNA的稳态似乎对USP1抑制的细胞毒性至关重要。 目前有几种USP1抑制剂正在进行临床I期试验-KSQ-4279/RO7623066(KSQ Therapeutics/Hoffmann-La Roche),ISM3091/XL309(In Silico Medicine/Exelixis),SIM0501(江苏先声药业有限公司),以及HSK39775(西藏海思科药业有限公司)。另一种USP1抑制剂,TNG348(Tango The...
LEXINGTON, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University of Texas MD...